Publications
Detailed Information
Treatment outcomes of multidrug-resistant TB with selective use of new drugs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Y-S | - |
dc.contributor.author | Shin, J.E. | - |
dc.contributor.author | Kang, H. | - |
dc.contributor.author | Jeon, D. | - |
dc.contributor.author | Yim, J-J | - |
dc.contributor.author | Shim, T.S. | - |
dc.date.accessioned | 2024-08-08T01:21:26Z | - |
dc.date.available | 2024-08-08T01:21:26Z | - |
dc.date.created | 2023-04-14 | - |
dc.date.created | 2023-04-14 | - |
dc.date.issued | 2023-01 | - |
dc.identifier.citation | International Journal of Tuberculosis and Lung Disease, Vol.27 No.1, pp.55-60 | - |
dc.identifier.issn | 1027-3719 | - |
dc.identifier.uri | https://hdl.handle.net/10371/205354 | - |
dc.description.abstract | SETTING: This was a nationwide cohort study.OBJECTIVE: To assess the treatment outcomes in patients with multidrug-resistant TB (MDR-TB) who underwent treatment guided by a national TB expert review committee in South Korea.DESIGN: We enrolled all patients with MDR-TB submitted for approval for the use of new TB drugs, including bedaquiline and delamanid, from 2016 to 2019. Patients were classified into two groups: those on new TB drugs and those not on new TB drugs. We compared the final treatment outcomes between the groups and analysed the prognostic factors.RESULTS: Of a total of 785 patients, respectively 754 (96.1%) and 31 (3.9%) were classified into the "new TB drugs" group and "no new TB drugs" group. The new TB drugs group had a higher acid-fast bacilli smear positivity rate and higher resistance rate to second-line injectable drugs or fluoroquinolones. Of all the patients, 97.8% achieved culture conversion (97.7% vs. 100%), and 80.4% achieved treatment success (80.2% vs. 86.7%); there was no difference between the two groups.CONCLUSIONS: New drugs are currently recommended for use in all MDR-TB treatment regimens, and the use of new drugs, as determined by an expert committee, in mainly quinolone-susceptible MDR-TB, did not compromise the treatment success rate. | - |
dc.language | 영어 | - |
dc.publisher | International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories | - |
dc.title | Treatment outcomes of multidrug-resistant TB with selective use of new drugs | - |
dc.type | Article | - |
dc.identifier.doi | 10.5588/ijtld.22.0343 | - |
dc.citation.journaltitle | International Journal of Tuberculosis and Lung Disease | - |
dc.identifier.wosid | 000992517700011 | - |
dc.identifier.scopusid | 2-s2.0-85149154634 | - |
dc.citation.endpage | 60 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 55 | - |
dc.citation.volume | 27 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Yim, J-J | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TUBERCULOSIS | - |
dc.subject.keywordPlus | BEDAQUILINE | - |
dc.subject.keywordPlus | DELAMANID | - |
dc.subject.keywordAuthor | bedaquiline | - |
dc.subject.keywordAuthor | delamanid | - |
dc.subject.keywordAuthor | multidrug-resistant tuberculosis | - |
dc.subject.keywordAuthor | expert committee | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.